Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be useful in treating individuals with marijuana dependence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Treatments: Selegiline

Criteria

Inclusion Criteria:

• Meets DSM-IV criteria for current marijuana dependence

• Positive urine toxicology test for marijuana

• Reports current marijuana use

• Weighs at least 100 lbs

• Women of childbearing age will be included provided they agree to use adequate contraception

Exclusion Criteria:

• Meets dependence or abuse criteria for alcohol

• Meets dependence criteria for illicit substances other than marijuana

• Serious medical disorders (such as unstable angina or liver failure), that may make participation in the trial unsafe

• Pregnant

• Currently diagnosed with a psychotic disorder

• Currently suicidal or pose a homicidal risk

• Currently taking over-the-counter (e.g., pseudoephedrine) or prescription (e.g., methylphenidate) sympathomimetic agents, antidepressant agents (e.g., tricyclic antidepressants, serotonin reuptake inhibitors, bupropion, other monoamine oxidase inhibitors), or meperidine (Demerol)

• Unable to understand English

• Known hypersensitivity to selegiline hydrochloride